Mahzi Therapeutics

07/30/2026

Patients are rarely given the chance to own a stake in the company developing the treatment they're waiting for. just shared the story of how Mahzi is changing that.

Join the families most affected. Investments start at $250. wefunder.com/mahzitherapeutics

In drug development, patients are the people a therapy is for. They enroll, they wait, they hope. What they almost never do is own a stake in the company racing to treat them. Yael Weiss built Mahzi Therapeutics to break that rule. Her clinical-stage biotech develops gene therapies for rare neurodev...

07/15/2026

Forbes covered how we built Mahzi differently 🧬. We’re writing patients into the capitalization table.

Families affected by rare diseases have historically contributed to research and now take ownership of the outcomes. Several of our early investors are parents of children with Pitt Hopkins Syndrome and they are alongside our professional investors Venrock, HealthCap, and Droia Ventures.

Thank you, Geri Stengel, for telling this story so well:

https://www.forbes.com/sites/geristengel/2026/07/13/this-biotech-lets-rare-disease-families-invest-in-its-gene-therapy/

Join them! Investments start at $250. https://wefunder.com/mahzi.therapeutics

Rare-disease families can now invest in Mahzi Therapeutics' gene therapy, giving patients a financial stake in developing treatments for their own communities

07/09/2026

The replay from our investor webinar is now live! 🎥

Thank you to everyone who joined us for our special webinar event this week. Audrey Davidow Lapidus, President of the Pitt Hopkins Research Foundation and mother of a son with Pitt Hopkins Syndrome, joined us to share what this work means to families living with the diseases we're working to treat.

Here's what we covered:
🧬 Where we are in the Phase 1/2 UNITE trial for Pitt Hopkins Syndrome
🔬 Our pipeline across Pitt Hopkins, WOREE/SCAR12, and CHD2
🤝 A candid conversation with Audrey about what it took to bring a gene therapy into trial
💡 The science behind MZ-1866 and what our preclinical findings showed

🎥 Watch the full recording here:
https://us02web.zoom.us/rec/share/xFUlSwBVlLyN15UQYnJsmuZMEF7XIcKWd5l0gXny9Hnn6uNDlg50HTRJ7DEahXzZ.WjYRR8rwBptVBDVw

There's still time to join us as an investor before we open the round to the public. Invest now or increase your investment at wefunder.com/mahzitherapeutics

Thank you for your continued support! 🩵

07/01/2026

Mahzi Therapeutics is hosting an exclusive webinar for our community before we open the round to the public. 🧬

Hear directly from our CEO and Founder, Yael Malkinson Weiss and our special guest, Audrey Davidow Lapidus, President & Founder of the Pitt Hopkins Research Foundation on Tuesday, July 7th at 10:00 AM PT / 1:00 PM ET.

📅 When: Tuesday, July 7 at 10:00 AM PT / 1:00 PM ET
👩‍🔬 Who: Yael Weiss, MD PhD (CEO & Founder) & Audrey Davidow Lapidus (President & Founder, PHRF)
🧬 What: Clinical updates, patient advocacy, and LIVE Q&A
📍 Where: Zoom Webinar

Know someone else who might be interested? Tag them or pass this along.

👉 Register now using this link: https://luma.com/x1x8931c.

06/17/2026

Welcome to Mahzi Therapeutics! 🧬

We're a clinical-stage biotech developing precision genetic therapies for children with rare forms of autism and seizure conditions who have no approved treatments.

Behind every program we run, there's a family. A parent who spent years searching for answers. A child with Pitt Hopkins Syndrome, WOREE, or CHD2 deficiency who deserves a chance to be seen and heard.

That's why we exist. Mahzi means "together" in Greek, and that's exactly how we work. We unite patient and family groups, academic researchers, and our internal team of experts to advance potentially transformative therapies for diseases that have been ignored for far too long.

Now, for the first time, we're inviting our community to invest alongside our venture capital investors. Learn more about our community investment round and reserve your investment now:
wefunder.com/mahzitherapeutics.

Together, we can bring treatments to families who have waited far too long. 🩵

Advancing precision therapies for rare neurodevelopmental diseases. Mahzi Therapeutics is testing the waters on Wefunder. Reserve your interest and foll...

06/12/2026

We love celebrating our small but mighty team! In fall 2025, our SVP of Regulatory, Jen Pavillard, created individualized team member awards to celebrate each person's involvement in getting our first IND submitted and later approved

05/27/2026

05/27/2026

Welcome to Mahzi Therapeutics!

We're a clinical-stage biotech developing precision genetic therapies for children with rare forms of autism and seizure conditions who have no approved treatments
Behind every program we run, there's a family. A parent who spent years searching for answers. A child with Pitt Hopkins Syndrome, WOREE, or CHD2 deficiency who deserves a chance to be seen and heard.

That's why we exist. Mahzi means "together" in Greek, and that's exactly how we work. We unite patient and family groups, academic researchers, and our internal team of experts to advance potentially transformative therapies for diseases that have been ignored for far too long.

Now, for the first time, we're inviting our community to invest alongside our venture capital investors. Learn more about our community investment round and reserve your investment now: wefunder.com/mahzitherapeutics.

Together, we can bring treatments to families who have waited far too long.